American Thoracic Society International Conference

At ATS 2026, investigators reported that pediatric pulmonary rehabilitation improved exercise capacity and quality of life in chronic respiratory disease.

A study presented at the ATS 2026 found the New York City Housing Authority’s Mold Busters program was associated with nearly 2800 fewer annual asthma-related ED visits.

Clinicians at ATS 2026 will see late-breaking COPD, asthma, and pulmonary hypertension data alongside exclusive interviews with leading experts in respiratory medicine.

Zulueta discussed Mount Sinai's incidental lung nodule program using AI tools to improve follow-up and recent findings from the program presented at ATS.

This Q&A interview highlights reductions observed in the use of rilzabrutinib for asthma symptom relief in a recent phase 2 study.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key pulmonology updates from the 2025 American Thoracic Society (ATS) International Conference.

During her ATS interview, Lisa Wood, PhD, spoke about economic and geographic disparities and their connection to diet and related respiratory health outcomes.

This ATS interview features Lisa Wood, PhD, discussing recent findings related to childhood dietary intake and its connection to respiratory health.

Bose explains her research on vaping among millennial adults who may be at peak lung health, describing the diverse landscape of vaping devices and products.

View conference highlights from HCPLive’s coverage of the American Thoracic Society (ATS) International Conference 2025.

In this interview, nerandomilast’s safety profile in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF) is highlighted.

Attaway reviews data demonstrating the potential benefit of a subspecialty clinic for overcoming current diagnostic and treatment-related challenges for sarcopenia in COPD.

This interview highlights phase 3 trial data on nerandomilast’s use in idiopathic pulmonary fibrosis (IPF) and progressive pulmonary fibrosis (PPF).

Prevot describes her research exploring the relationship between OSA severity and abdominal obesity metrics as well as changes in both metrics following CPAP.

These data from ATS 2025 highlight patients’ real-world outcomes related to treatment of their chronic obstructive pulmonary disease (COPD) with dupilumab.

The analysis of pooled data from BOREAS and NOTUS highlight dupilumab’s sustained impact on lung function in patients with COPD and type 2 inflammation.

In this interview, Chalmers highlights the implications of his team’s subgroup analysis findings in the ASPEN trial, as well as unmet needs for non-cystic fibrosis bronchiectasis.

Findings from a post hoc analysis of the phase 3 DIRECTION study highlight tezepelumab’s consistent benefit on asthma exacerbations across trigger categories.

At ATS 2025, these data highlight a potential connection between asthma development and prenatal exposure to microplastics and other forms of pollution.

This interview highlights the subgroup analysis findings of the ASPEN trial, specifically on brensocatib for non-cystic fibrosis bronchiectasis.

This special episode of Lungcast features Harold P. Wimmer, CEO of the ALA, and Francesca Polverino, MD, PhD, an ALA spokesperson.

Gerard Criner, MD, reviews findings from a secondary analysis of the phase 3 MATINEE trial of mepolizumab and looks ahead to the potential significance of the drug, if approved.

In her interview at ATS, Willen further described elements highlighted in her presentation on new treatments for sickle cell disease.

This interview at ATS 2025 features a discussion of a ‘Pediatric Year in Review’ presentation on new therapies for sickle cell disease.

Stoller describes the potential of a novel AI model to help address AATD underrecognition, citing findings from his research on its performance in a Cleveland Clinic cohort.

This interview highlights the long-term, late-breaking results of the A DUE trial’s 24-month open-label extension on macitentan and tadalafil for PAH.

Criner reviews findings from AIRFLOW-3 and describes the subgroup of targeted lung denervation treatment responders being targeted in AIRFLOW-4.

Results highlight dupilumab’s real-world benefit for asthma control in patients with and without coexisting chronic rhinosinusitis and/or nasal polyposis.

At ATS 2025, these post-hoc analysis findings on taladegib (ENV-101) highlight the treatment’s efficacy for idiopathic pulmonary fibrosis.

Attaway describes the importance of screening for and treating sarcopenia in patients with COPD and clinical gaps that complicate this process.